Neumora Therapeutics Inc (NMRA)
1.1300 x 20 1.1900 x 16
Post-market by (Cboe BZX)
1.1300 -0.0300 (-2.59%) 03/21/25 [NASDAQ]
1.1300 x 20 1.1900 x 16
Post-market 1.1300 unch (unch) 16:22 ET
for Fri, Mar 21st, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | |
Assets | |||
Current Assets | |||
Cash & Cash Equivalents | 143,361 | 374,038 | 240,993 |
Marketable Securities | 165,430 | 79,944 | 130,941 |
TOTAL | $314,055 | $478,279 | $387,955 |
Non-Current Assets | |||
PPE Net | 1,140 | 1,790 | 2,411 |
Investments And Advances | 0 | 9,845 | 23,511 |
Other Non-Current Assets | 1,777 | 6,281 | 12,357 |
TOTAL | $2,917 | $17,916 | $38,279 |
Total Assets | $316,972 | $496,195 | $426,234 |
Liabilities | |||
Current Liabilities | |||
Accounts payable and accrued liabilities | 3,307 | 337 | 7,147 |
Accrued Expenses | 24,593 | 21,257 | 11,536 |
Other current liabilities | 133 | 139 | 1,644 |
TOTAL | $29,886 | $25,111 | $23,697 |
Non-Current Liabilities | |||
aiOther Non-Current Liabilities | 22 | 2,008 | 5,700 |
TOTAL | $22 | $2,008 | $5,700 |
Total Liabilities | $29,908 | $27,119 | $29,397 |
Shareholders' Equity | |||
Shares Outstanding, K | 161,979 | 158,886 | N/A |
Common Shares | 16 | 16 | 3 |
Retained earnings | -947,221 | -703,434 | -467,509 |
Other shareholders' equity | 62 | -76 | 842,913 |
TOTAL | $287,064 | $469,076 | $396,837 |
Total Liabilities And Equity | $316,972 | $496,195 | $426,234 |